Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure

Tat basic domain: A “Swiss army knife” of HIV-1 Tat?

(2019) Margarita A. Kurnaeva et al.   REVIEWS IN MEDICAL VIROLOGY

HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy

(2019) Yonatan Ganor et al.   Nature Microbiology

Entry of Polarized Effector Cells into Quiescence Forces HIV Latency

(2019) Curtis Dobrowolski et al.   mBio

Didehydro-Cortistatin A Inhibits HIV-1 by Specifically Binding to the Unstructured Basic Region of Tat

(2019) Sonia Mediouni et al.   mBio

HIV Transcription is Independent of Mediator Kinases

(2019) Daniele C. Cary et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

The Tat inhibitor didehydro-cortistatin A suppresses SIV replication and reactivation

(2019) Sonia Mediouni et al.   FASEB JOURNAL

Inhibition of RNA polymerase III transcription by Triptolide attenuates colorectal tumorigenesis

(2019) Xia Liang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Tat inhibition by didehydro-Cortistatin A promotes heterochromatin formation at the HIV-1 long terminal repeat

(2019) Chuan Li et al.   Epigenetics & Chromatin

Modeling the effect of tat inhibitors on HIV latency

(2019) Luis U. Aguilera et al.   JOURNAL OF THEORETICAL BIOLOGY

Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription

(2019) Guillaume Mousseau et al.   mBio

HIV Silencing and Inducibility Are Heterogeneous and Are Affected by Factors Intrinsic to the Virus

(2019) Nicholas J. Norton et al.   mBio

Unexpected Mutations in HIV-1 That Confer Resistance to the Tat Inhibitor Didehydro-Cortistatin A

(2019) Andrew P. Rice   mBio

Deep latency: A new insight into a functional HIV cure

(2019) Maher M. Elsheikh et al.   EBioMedicine

Strong In Vivo Inhibition of HIV-1 Replication by Nullbasic, a Tat Mutant

(2019) Hongping Jin et al.   mBio

Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease

(2019) Aurelio Cafaro et al.   Vaccines

Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa

(2019) Jon Cantero-Pérez et al.   Nature Communications

New Challenges of HIV-1 Infection: How HIV-1 Attacks and Resides in the Central Nervous System

(2019) Victoria Rojas-Celis et al.   Cells

Getting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIV

(2018) Youry Kim et al.   Cell Host & Microbe

The Effect of Triptolide in Rheumatoid Arthritis: From Basic Research towards Clinical Translation

(2018) Danping Fan et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

HIV Preexposure Prophylaxis

(2018) James Riddell et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection

(2018) Donn J. Colby et al.   NATURE MEDICINE

Born to run: control of transcription elongation by RNA polymerase II

(2018) Fei Xavier Chen et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Defining the molecular mechanisms of HIV-1 Tat secretion: PtdIns(4,5)P2 at the epicenter

(2018) Anthony R Mele et al.   TRAFFIC

A Mechanistic Overview of Triptolide and Celastrol, Natural Products from Tripterygium wilfordii Hook F

(2018) Shao-Ru Chen et al.   Frontiers in Pharmacology

Macrophages but not Astrocytes Harbor HIV DNA in the Brains of HIV-1-Infected Aviremic Individuals on Suppressive Antiretroviral Therapy

(2018) Allen Ko et al.   Journal of Neuroimmune Pharmacology

Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line

(2018) Seung Tae Kim et al.   BMC CANCER

Probabilistic control of HIV latency and transactivation by the Tat gene circuit

(2018) Youfang Cao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency

(2018) Todd Bradley et al.   Cell Reports

HEXIM1-Tat chimera inhibits HIV-1 replication

(2018) Marie Leoz et al.   PLoS Pathogens

Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4 + T Cells Permissive for Latent HIV-1 Infection

(2017) Liang Shan et al.   IMMUNITY

A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy

(2017) Mariluz Araínga et al.   Retrovirology

HIV Latency: Should We Shock or Lock?

(2017) Gilles Darcis et al.   TRENDS IN IMMUNOLOGY

A mutant Tat protein inhibits infection of human cells by strains from diverse HIV-1 subtypes

(2017) Lina Rustanti et al.   Virology Journal

Tat is a multifunctional viral protein that modulates cellular gene expression and functions

(2017) Evan Clark et al.   Oncotarget

In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a “Block-and-Lock” Strategy for HIV-1 Treatment

(2017) Cari F. Kessing et al.   Cell Reports

HIV-1 Tat and Viral Latency: What We Can Learn from Naturally Occurring Sequence Variations

(2017) Doreen Kamori et al.   Frontiers in Microbiology

Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation

(2017) Maxime J. Jean et al.   Frontiers in Microbiology

Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals

(2016) Amy E. Baxter et al.   Cell Host & Microbe

The mTOR Complex Controls HIV Latency

(2016) Emilie Besnard et al.   Cell Host & Microbe

Recent advances in the identification of Tat-mediated transactivation inhibitors: progressing toward a functional cure of HIV

(2016) Oriana Tabarrini et al.   Future Medicinal Chemistry

Molecular mechanisms of HIV latency

(2016) Daniele C. Cary et al.   JOURNAL OF CLINICAL INVESTIGATION

Cracking the control of RNA polymerase II elongation by 7SK snRNP and P-TEFb

(2016) Alexandre J. C. Quaresma et al.   NUCLEIC ACIDS RESEARCH

HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial

(2016) Barbara Ensoli et al.   Retrovirology

Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial

(2016) Erwann P. Loret et al.   Retrovirology

Latency reversal and viral clearance to cure HIV-1

(2016) D. M. Margolis et al.   SCIENCE

Shutdown of HIV-1 Transcription in T Cells by Nullbasic, a Mutant Tat Protein

(2016) Hongping Jin et al.   mBio

Tissue reservoirs of HIV

(2016) Joseph K. Wong et al.   Current Opinion in HIV and AIDS

LEDGIN-mediated Inhibition of Integrase–LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV

(2016) Lenard S. Vranckx et al.   EBioMedicine

Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a HSP90-dependent manner

(2016) Hong Kim et al.   Scientific Reports

Understanding HIV Latency: The Road to an HIV Cure

(2015) Matthew S. Dahabieh et al.   Annual Review of Medicine

A Hardwired HIV Latency Program

(2015) Brandon S. Razooky et al.   CELL

Didehydro-Cortistatin A Inhibits HIV-1 Tat Mediated Neuroinflammation and Prevents Potentiation of Cocaine Reward in Tat Transgenic Mice

(2015) Sonia Mediouni et al.   CURRENT HIV RESEARCH

Stably paused genes revealed through inhibition of transcription initiation by the TFIIH inhibitor triptolide

(2015) Fei Chen et al.   GENES & DEVELOPMENT

The Remarkable Stability of the Latent Reservoir for HIV-1 in Resting Memory CD4+T Cells

(2015) Janet M. Siliciano et al.   JOURNAL OF INFECTIOUS DISEASES

Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies

(2015) Amanda M. Crooks et al.   JOURNAL OF INFECTIOUS DISEASES

A Mutant Tat Protein Inhibits HIV-1 Reverse Transcription by Targeting the Reverse Transcription Complex

(2015) Min-Hsuan Lin et al.   JOURNAL OF VIROLOGY

Mediator kinase inhibition further activates super-enhancer-associated genes in AML

(2015) Henry E. Pelish et al.   NATURE

HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial

(2015) Fabrizio Ensoli et al.   Retrovirology

The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency

(2015) Guillaume Mousseau et al.   mBio

An Ounce of Tat Prevention Is Worth a Pound of Functional Cure: FIG 1 

(2015) Vicente Planelles   mBio

Changes in HIV reservoirs during long-term antiretroviral therapy

(2015) Feiyu F. Hong et al.   Current Opinion in HIV and AIDS

HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells

(2015) Leonard Chavez et al.   PLoS Pathogens

Heat shock protein 90 controls HIV-1 reactivation from latency

(2014) I. Anderson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study

(2014) Stefania Bellino et al.   Retrovirology

A HIV-1 Tat mutant protein disrupts HIV-1 Rev function by targeting the DEAD-box RNA helicase DDX1

(2014) Min-Hsuan Lin et al.   Retrovirology

Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein

(2014) Zhitao Wan et al.   Retrovirology

Revisiting transdominant-negative proteins in HIV gene therapy

(2013) Haran Sivakumaran et al.   Future Virology

A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+ T Cells

(2013) Ann Apolloni et al.   HUMAN GENE THERAPY

Dynamic interactions of the HIV-1 Tat with nucleic acids are critical for Tat activity in reverse transcription

(2013) C. Boudier et al.   NUCLEIC ACIDS RESEARCH

Characterization of Tat Antibody Responses in Chinese Individuals Infected with HIV-1

(2013) Qiuli Chen et al.   PLoS One

HIV-1 transcription and latency: an update

(2013) Carine Van Lint et al.   Retrovirology

Overexpression of PRMT6 does not suppress HIV-1 Tat transactivation in cells naturally lacking PRMT6

(2013) Haran Sivakumaran et al.   Virology Journal

An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients

(2013) Celsa A. Spina et al.   PLoS Pathogens

An Analog of the Natural Steroidal Alkaloid Cortistatin A Potently Suppresses Tat-Dependent HIV Transcription

(2012) Guillaume Mousseau et al.   Cell Host & Microbe

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

(2012) Camellia Banerjee et al.   JOURNAL OF LEUKOCYTE BIOLOGY

An AP-1 Binding Site in the Enhancer/Core Element of the HIV-1 Promoter Controls the Ability of HIV-1 To Establish Latent Infection

(2012) A. Duverger et al.   JOURNAL OF VIROLOGY

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

Nullbasic, a Potent Anti-HIV Tat Mutant, Induces CRM1-Dependent Disruption of HIV Rev Trafficking

(2012) Min-Hsuan Lin et al.   PLoS One

Scalable Synthesis of Cortistatin A and Related Structures

(2011) Jun Shi et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy

(2011) Alex Sigal et al.   NATURE

XPB, a subunit of TFIIH, is a target of the natural product triptolide

(2011) Denis V Titov et al.   Nature Chemical Biology

Triptolide (TPL) Inhibits Global Transcription by Inducing Proteasome-Dependent Degradation of RNA Polymerase II (Pol II)

(2011) Ying Wang et al.   PLoS One

A Chinese herb Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: mechanism, efficacy, and safety

(2011) Jun Bao et al.   RHEUMATOLOGY INTERNATIONAL

Crystal structure of HIV-1 Tat complexed with human P-TEFb

(2010) Tahir H. Tahirov et al.   NATURE

Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART

(2010) Barbara Ensoli et al.   PLoS One

HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals

(2010) D. Trono et al.   SCIENCE

Transcription through the HIV-1 nucleosomes: Effects of the PBAF complex in Tat activated transcription

(2010) Rebecca Easley et al.   VIROLOGY

Epigenetic regulation of HIV latency

(2010) Shweta Hakre et al.   Current Opinion in HIV and AIDS

Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid

(2009) Nancie M. Archin et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Cortistatin A is a High-Affinity Ligand of Protein Kinases ROCK, CDK8, and CDK11

(2009) Victor J. Cee et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

HIV-1 Tat is unconventionally secreted through the plasma membrane

(2009) Fabienne Rayne et al.   CELL BIOLOGY INTERNATIONAL

Stochastic gene expression as a molecular switch for viral latency

(2009) Abhyudai Singh et al.   CURRENT OPINION IN MICROBIOLOGY

Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells

(2009) Xavier Contreras et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA

(2009) S. Vispe et al.   MOLECULAR CANCER THERAPEUTICS

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

(2009) Nicolas Chomont et al.   NATURE MEDICINE

Potent Inhibition of HIV-1 Replication by a Tat Mutant

(2009) Luke W. Meredith et al.   PLoS One

The preventive phase I trial with the HIV-1 Tat-based vaccine

(2009) Barbara Ensoli et al.   VACCINE

Cellular Reservoirs of HIV-1 and their Role in Viral Persistence

(2008) Aikaterini Alexaki et al.   CURRENT HIV RESEARCH